J&J Consumer Health Has Digital And Natural Drivers For ‘Above Market’ Growth

OTC drug sales grew worldwide 4.4% on an operational basis to $4.34bn, with US segment driving increase. US OTC sales jumped 7.8% to reach $1.85bn and international sales grew 2.1% to $2.48bn. J&J consumer segment got a lift from mid-year addition of Zarbees.

4th quarter computer key on key board

An emphasis Johnson & Johnson made at the start of 2018 on growing digital sales and a mid-year move into the natural supplements category were key drivers for its 3.2% consumer health sales growth for the year.

OTC drugs including Tylenol and Motrin analgesics, the Neutrogena and OGX beauty lines and the Listerine oral care brand drove...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Business

More from Wellness